Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies
For patients with gout and type 2 diabetes, SGLT2is may reduce gout-related medication use, which could, in turn, reduce exposure to the harmful cardiovascular-kidney-metabolic effects of NSAIDs and glucocorticoids in this high-risk population.
Authors
- Sharan Rai
- Rozalina Grubina McCoy (ORCID: https://orcid.org/0000-0002-2289-3183)
- Gregory J. Challener (ORCID: https://orcid.org/0000-0002-2844-4661)
- Ran Abuhasira (ORCID: https://orcid.org/0000-0001-7031-6498)
- Nitzan Burrack (ORCID: https://orcid.org/0000-0001-6926-8505)
- Na Lü (ORCID: https://orcid.org/0000-0001-7585-4279)
- J. Antonio Aviña-Zubieta
- Chio Yokose
- Hyon K. Choi
- Deborah J. Wexler
Institutions
- University of Maryland, Baltimore (US)
- Harvard University (US)
- University of British Columbia (CA)
- Soroka Medical Center (IL)
- Foundation for the National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Research Canada (CA)
- ENT and Allergy (US)
- Arthritis Research Centre of Canada (CA)
Publication Details
- Journal
- Diabetes Care
- Published
- 2026-01-30
- DOI
- https://doi.org/10.2337/dc25-1713
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 0.00